Back to results
US 11,447,564 B2Granted
Constructs specifically recognizing glypican 3 and uses thereof
AssigneeEureka Therapeutics, Inc.
InventorsPengbo Zhang, Yiyang Xu, Javier Morales, Yoko Nakano, Hong Liu, Jingyi Xiang, Timothy Acker
Life of this patent
Estimating the term…
Abstract
The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.
Claims25
An isolated anti-Glypican-3 (anti-GPC3) construct comprising an antibody moiety specifically recognizing GPC3 (anti-GPC3 antibody moiety), wherein the anti-GPC3 antibody moiety comprises:
- (1) a heavy chain complementarity determining region (HC-CDR) 1 comprising the amino acid sequence of SEQ ID NO:
- 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 54, an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 105, a light chain complementarity determining region (LC-CDR) 1 comprising the amino acid sequence of SEQ ID NO:
- 156, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 207, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 258;
- (2) an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 21, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 72, an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 123, an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 174, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 225, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 276;
- (3) an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 24, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 75, an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 126, an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 177, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 228, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 279;
- (4) an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 52, an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 103, an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 154, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 205, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 256;
- (5) an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 11, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 62, an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 113, an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 164, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 215, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 266;
- or
- (6) an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 63, an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 114, an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 165, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 216, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 267.
40 more elements
Dependencies are inferred from the claim text.